Browsing Tag
Parkinson’s disease
18 posts
Can AI-guided delivery platforms reshape CNS drug development? Inside the Mercury Bio and Meta-Flux alliance
Mercury Bio and Meta-Flux are teaming up to tackle Parkinson's and Alzheimer's with AI-powered simulation and next-gen delivery. Can this reshape CNS drug development?
Vimgreen Pharmaceuticals progresses with Phase 2 trial of VG081821AC for Parkinson’s disease
Vimgreen Pharmaceuticals has marked a significant milestone with the completion of participant enrollment in its Phase 2 clinical…
PhotoPharmics reaches key milestone in Light for PD trial for Parkinson’s disease
PhotoPharmics, a leader in neurodegenerative disease phototherapy, has reached a significant milestone in its Light for PD clinical…
Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition…
Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease
Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a journey…
Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical…
Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1
Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA’s approval to commence Phase II…
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will…
SPARC achieves enrollment goal in PROSEEK Phase 2 Parkinson’s trial
Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the successful completion of patient enrollment for the PROSEEK…
ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301
ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to…